Regional isolation perfusion in the treatment of advanced malignant disease.
Regional isolation perfusion with an alkylating agent was carried out in a small community hospital, using readily available equipment, ten times in nine cases of advanced malignant disease. Visible regression of tumor, either grossly or histologically, occurred in seven patients and decided subjective improvement occurred in five patients. The long range effect of the procedure could not be determined in the present series, not enough time having elapsed. Side effects included jaundice in four patients, massive necrosis of the tumor in one patient, nausea and vomiting in three patients, postoperative edema in five patients, wound infection in two patients, Horner's syndrome in one patient, temporary alopecia in three patients, and depression of hemoglobin level in seven patients, of the leukocyte count in four patients and of the platelet count in four patients.A feature of the procedure used in the present series was a system of monitoring the escape of alkylating agent into the systemic circulation.
D000970:Antineoplastic Agents / Q000628:therapy*; D010478:Chemotherapy, Cancer, Regional Perfusion; D004487:Edema; D005112:Extracorporeal Circulation; D005260:Female; D006801:Humans; D008297:Male; D008558:Melphalan; D008875:Middle Aged; D009369:Neoplasms; D010477:Perfusion; D014409:Tumor Necrosis Factor-alpha
D000970:Antineoplastic Agents; D014409:Tumor Necrosis Factor-alpha; D008558:Melphalan
ANTINEOPLASTIC AGENTS/therapy; PERFUSION